Investment Analysts’ Recent Ratings Changes for SiBone (SIBN)

SiBone (NASDAQ: SIBN) has recently received a number of price target changes and ratings updates:

• 7/28/2026 – SiBone is now covered by UBS Group AG. They set a “buy” rating and a $24.00 price target on the stock.
• 7/28/2026 – SiBone is now covered by UBS Group AG. They set a “buy” rating and a $24.00 price target on the stock.
• 7/21/2026 – SiBone was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 7/16/2026 – SiBone had its price target raised by Truist Financial Corporation from $18.00 to $21.00. They now have a “buy” rating on the stock.
• 7/2/2026 – SiBone had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Insider Buying and Selling at SiBone

In other SiBone news, Director Timothy E. Davis, Jr. sold 3,780 shares of the firm’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $14.47, for a total value of $54,696.60. Following the completion of the sale, the director owned 69,222 shares of the company’s stock, valued at $1,001,642.34. This trade represents a 5.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Laura Francis sold 14,957 shares of the firm’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $14.71, for a total value of $220,017.47. Following the sale, the chief executive officer directly owned 503,444 shares of the company’s stock, valued at $7,405,661.24. This represents a 2.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 35,989 shares of company stock valued at $541,229. Insiders own 4.00% of the company’s stock.

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.